Actively Recruiting
Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients
Led by Yonsei University · Updated on 2023-08-30
3434
Participants Needed
1
Research Sites
297 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Clopidogrel monotherapy has been found effective in reducing ischaemic cardiovascular and haemorrhagic complications in patients with drug-eluting stent (DES) placement. However, concerns remain about the safety of long-term clopidogrel monotherapy in high-risk patients with HPR (high platelet reactivity) who do not respond adequately to clopidogrel. This study aims to evaluate the effectiveness of a patient-tailored antiplatelet therapy strategy that considers platelet aggregation in high-risk patients with DES placement beyond 12 months after stenting.
CONDITIONS
Official Title
Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years
- Underwent percutaneous coronary intervention with drug-eluting stent placement 12 months (± 3 months) ago
- Have at least one high-risk characteristic for ischemic events, including acute coronary syndrome, previous stroke, peripheral artery intervention, heart failure, diabetes requiring medication, or chronic kidney disease
- Have high-risk lesions such as left main disease, multivessel disease, bifurcation lesions needing 2+ stents, chronic total occlusion, in-stent restenosis, graft lesions, diffuse long lesions needing stents totaling ≥28 mm, stent diameter ≤2.5 mm, or calcified lesions requiring atherectomy
You will not qualify if you...
- Patients older than 80 years
- Pregnant women or women who may become pregnant
- Life expectancy less than 1 year
- Unable or unwilling to give informed consent
- Eligible for long-term anticoagulation therapy
- Major bleeding event in the 3 months before randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Severance Hospital
Seoul, South Korea
Actively Recruiting
Research Team
B
Byeong-Keuk Kim
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here